Catalent, Rayaldee and thestree
Sept 14, 2016 9:15:36 GMT
via Tapatalk
icemandios, investobefree22, and 2 more like this
Post by stcks on Sept 14, 2016 9:15:36 GMT
This is from thestree and is dated 9-9-2016. Sorry if people have talked about this on before.
What I find surprising here is they talk more positively about the effect of sales of Rayaldee on Catalent bottom line, then most people do on OPKO's bottom line.
www.thestreet.com/story/13697296/1/2-big-companies-and-1-small-one-to-target-in-the-pharma-biotech-space.html
Catalent's key growth drivers are new product technology offerings in its core Softgel segment. For example OptiShell, has been selected for use by OPKO Health for its newly-approved Rayaldee treatment for Secondary Hyperparathyroidism, which often accompanies Chronic Kidney Disease. Also expected to fuel future growth at Catalent are its new GPEx cell-line and SMARTag antibody-drug conjugation technologies in its Biologics group.
In its most recent fourth quarter earnings release (ending June 2016), Catalent reached 6% revenue growth (on a constant currency basis) to $532.2 million, and $0.46 per share in earnings, while adjusted EBITDA grew 7% year-over-year. Management guidance for the June 2017 fiscal year are revenues in the $1.9-$2.0 billion range, or an increase of 4%-6% over fiscal 2016, with earnings per share in the range of approximately $1.25-$1.50, a solid improvement from $0.89 per share in fiscal 2016. Key catalysts coming up for Catalent are new partner product launches such as Rayaldee and Nexium 24HR, re-opening of a manufacturing facility in France, and growth in research collaborations and clinical supplies in the biologics segment.
What I find surprising here is they talk more positively about the effect of sales of Rayaldee on Catalent bottom line, then most people do on OPKO's bottom line.
www.thestreet.com/story/13697296/1/2-big-companies-and-1-small-one-to-target-in-the-pharma-biotech-space.html
Catalent's key growth drivers are new product technology offerings in its core Softgel segment. For example OptiShell, has been selected for use by OPKO Health for its newly-approved Rayaldee treatment for Secondary Hyperparathyroidism, which often accompanies Chronic Kidney Disease. Also expected to fuel future growth at Catalent are its new GPEx cell-line and SMARTag antibody-drug conjugation technologies in its Biologics group.
In its most recent fourth quarter earnings release (ending June 2016), Catalent reached 6% revenue growth (on a constant currency basis) to $532.2 million, and $0.46 per share in earnings, while adjusted EBITDA grew 7% year-over-year. Management guidance for the June 2017 fiscal year are revenues in the $1.9-$2.0 billion range, or an increase of 4%-6% over fiscal 2016, with earnings per share in the range of approximately $1.25-$1.50, a solid improvement from $0.89 per share in fiscal 2016. Key catalysts coming up for Catalent are new partner product launches such as Rayaldee and Nexium 24HR, re-opening of a manufacturing facility in France, and growth in research collaborations and clinical supplies in the biologics segment.
